Management of hypertension: considerations involving cardiovascular risk reduction

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Hypertension management traditionally focuses on blood pressure reduction.
• This surrogate goal may not fully translate to reducing cardiovascular and renal complications.
• The effectiveness of current antihypertensive strategies in preventing atherosclerosis and related events needs re-evaluation.

Purpose of the Study:

• To examine the premise that blood pressure reduction is the ultimate goal in hypertension therapy.
• To investigate the potential contribution of metabolic disarray from antihypertensive agents to cardiovascular events.
• To explore whether the choice of antihypertensive agent influences outcomes beyond blood pressure control.

Main Methods:

• Review of clinical trial data and underlying mechanisms of hypertension.
• Analysis of observations linking antihypertensive agents to metabolic abnormalities.
• Examination of selective responses of left ventricular hypertrophy and renal injury to different agents.

Main Results:

• Antihypertensive therapy has not significantly impacted atherosclerosis progression or coronary events.
• Metabolic disarray, including electrolyte abnormalities and insulin resistance, is linked to certain antihypertensive agents (e.g., thiazides, beta-blockers).
• Left ventricular hypertrophy and renal injury progression show selective sensitivity to different antihypertensive agents.

Conclusions:

• Blood pressure reduction alone may be insufficient for comprehensive hypertension management.
• The selection of antihypertensive agents may significantly influence metabolic profiles and clinical outcomes.
• Future hypertension therapy should consider factors beyond blood pressure reduction to mitigate cardiovascular and renal risks.